Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use
Abstract
Background and Aims: Immune checkpoint–inhibitor (ICI) colitis is a common adverse event that is primarily treated with corticosteroids but may require selective immunosuppressive therapy (SIT). Although endoscopic features have been associated with SIT use, it remains unclear whether these associations differ by ICI type.
Methods: We conducted a 2-center retrospective cohort study and included patients with histologically confirmed ICI colitis. Endoscopic images were reviewed by gastroenterologists specialized in inflammatory bowel disease (IBD) and scored using the Mayo score and the Immune-Mediated Colitis Endoscopic Score (IMCES). Early SIT use was defined as SIT use within 3 weeks after the start of colitis treatment. Features associated with SIT use were stratified by ICI type, and discriminative performance was evaluated using receiver operating characteristic (ROC) analysis.
Results: Among 255 included patients, 38% required SIT. Biochemical parameters associated with early SIT use were C-reactive protein (CRP) (odds ratio (OR), 1.41; P = .005), and albumin (OR, 0.92; P = .020). Endoscopic features associated with SIT use included erythema (OR, 4.09; P = .006) and exudate (OR, 3.24; P = .012), which were limited to patients treated with anti-cytotoxic T-lymphocyte-associated antigen 4–based (aCTLA-4–based) therapy. In multivariable analysis, ICI type remained the only variable associated with early SIT use (OR, 12.8; P < .001). The IMCES demonstrated areas under the curves (AUCs) of 0.57 (95% CI, 0.50-0.65) for overall and 0.61 (95% CI, 0.53-0.69) for early SIT use.
Conclusions: In patients with ICI colitis, escalation to SIT use was primarily associated with ICI type, with limited additional value of biochemical or endoscopic features. The IMCES showed poor predictive performance in this external validation cohort.
Related
- Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis
- Immune checkpoint inhibitor-associated interstitial nephritis: let’s move forward addressing the unknowns
- Beyond Steroids: Mycophenolate Mofetil Dosing in Immune Checkpoint Inhibitor-Mediated Hepatitis
- Fatal Coronary and Mesenteric Vasculopathy With Immune Checkpoint Inhibitor Therapy
- 1010 HLA-B allele frequencies in immune checkpoint inhibitor-associated rheumatologic adverse events
BibTeX
@article{naber2026clinical,
title = {{Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use}},
author = {Myrthe R Naber and Mick J M van Eijs and Jildou S Huitema and Jacco J de Haan and Karijn P M Suijkerbuijk and Marijn C Visschedijk and Fiona D M van Schaik},
journal = {Inflammatory Bowel Diseases},
year = {2026},
month = aug,
doi = {10.1093/ibd/izag104},
url = {https://doi.org/10.1093/ibd/izag104},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical and endoscopic features of checkpoint inhibitor–induced colitis and their association with selective immunosuppressive therapy use
AU - Myrthe R Naber
AU - Mick J M van Eijs
AU - Jildou S Huitema
AU - Jacco J de Haan
AU - Karijn P M Suijkerbuijk
AU - Marijn C Visschedijk
AU - Fiona D M van Schaik
PY - 2026
DA - 2026/08/21
JO - Inflammatory Bowel Diseases
DO - 10.1093/ibd/izag104
UR - https://doi.org/10.1093/ibd/izag104
AB - Background and Aims: Immune checkpoint–inhibitor (ICI) colitis is a common adverse event that is primarily treated with corticosteroids but may require selective immunosuppressive therapy (SIT). Although endoscopic features have been associated with SIT use, it remains unclear whether these associations differ by ICI type. Methods: We conducted a 2-center retrospective cohort study and included patients with histologically confirmed ICI colitis. Endoscopic images were reviewed by gastroenterologists specialized in inflammatory bowel disease (IBD) and scored using the Mayo score and the Immune-Mediated Colitis Endoscopic Score (IMCES). Early SIT use was defined as SIT use within 3 weeks after the start of colitis treatment. Features associated with SIT use were stratified by ICI type, and discriminative performance was evaluated using receiver operating characteristic (ROC) analysis. Results: Among 255 included patients, 38% required SIT. Biochemical parameters associated with early SIT use were C-reactive protein (CRP) (odds ratio (OR), 1.41; P = .005), and albumin (OR, 0.92; P = .020). Endoscopic features associated with SIT use included erythema (OR, 4.09; P = .006) and exudate (OR, 3.24; P = .012), which were limited to patients treated with anti-cytotoxic T-lymphocyte-associated antigen 4–based (aCTLA-4–based) therapy. In multivariable analysis, ICI type remained the only variable associated with early SIT use (OR, 12.8; P < .001). The IMCES demonstrated areas under the curves (AUCs) of 0.57 (95% CI, 0.50-0.65) for overall and 0.61 (95% CI, 0.53-0.69) for early SIT use. Conclusions: In patients with ICI colitis, escalation to SIT use was primarily associated with ICI type, with limited additional value of biochemical or endoscopic features. The IMCES showed poor predictive performance in this external validation cohort.
SN - 1078-0998
SN - 1536-4844
ER -